摘要
目的:比较分析超声造影与增强CT对经导管肝动脉化疗栓塞术(TACE)治疗原发性肝癌疗效的评估价值。方法:以本院2015年1月至2017年12月行TACE治疗的70例原发性肝癌患者为研究对象,所有患者术后1个月行超声造影、增强CT及数字减影血管造影(DSA)检查,以DSA为金标准,比较超声造影、增强CT对TACE疗效评价的灵敏度、特异度及准确度。结果:DSA复查显示病灶残留(阳性)63个,阴性31个;以DSA为金标准,超声造影诊断残留病灶(阳性)灵敏度、特异度、准确度分别为95.24%、100.00%、96.81%,增强CT诊断灵敏度、特异度、准确度分别为84.13%、100.00%、89.36%,超声造影诊断灵敏度、准确度均显著高于增强CT(P<0.05)。结论:相比增强CT,超声造影对原发性肝癌TACE治疗后病灶残留诊断灵敏度、准确度均显著高,为TACE治疗原发性肝癌疗效评估有效手段。
Objective:To comparatively analyze the value of contrast-enhanced ultrasound and enhanced CT in evaluating the curative effect of transcatheter arterial chemoembolization(TACE)in the treatment of primary liver cancer.Methods:70 patients with primary liver cancer treated by TACE in the hospital from January 2015 to December 2017 were selected as the subjects.All patients were examined by contrast-enhanced ultrasound,enhanced CT and digital subtraction angiography(DSA)at 1 month after operation.With DSA as the golden standard,the sensitivity,specificity and accuracy of contrast-enhanced ultrasound and enhanced CT in evaluating the curative effect of TACE were compared.Results:DSA showed 63 residual lesions(positive)and 31 negative lesions.With DSA as the golden standard,the sensitivity,specificity and accuracy of contrast-enhanced ultrasound in the diagnosis of residual lesions(positive)(95.24%,100.00%and 96.81%)were significantly higher than those of enhanced CT(84.13%,100.00%and 89.36%)(P<0.05).Conclusion:Compared with contrast-enhanced CT,the sensitivity and accuracy of contrast-enhanced ultrasound are significantly higher in diagnosing residual lesions after TACE for primary liver cancer.It is an effective method for evaluating the curative effect of TACE in the treatment of primary liver cancer.
作者
王曦
李东
何芬
邓旦
徐丹
WANG Xi;LI Dong;HE Fen(Chengdu Military Region General Hospital,Sichuan Chengdu 610083,China)
出处
《河北医学》
CAS
2018年第7期1113-1116,共4页
Hebei Medicine
基金
四川省科技厅科技支撑计划项目
(编号:2015FZ0073)
关键词
超声造影
增强CT
经导管肝动脉化疗栓塞术
原发性肝癌
Ultrasound contrast
Enhanced CT
Transcatheter arterial chemoembolization
Primary carcinoma of liver
